Par Pharma (PRX) Moves Higher on Extended Outlook

Par Pharma (NYSE: PRX) is on the rise Friday, following an issued outlook from a recent presentation filed with the U.S. SEC.

According to the filing:

For fiscal 2012 to 2014, expectations are:

• Cumulative EPS of at lease $12.50 for the three periods;
  
• Adjusted gross margin rates approaching 50 percent;
  
• R&D spending of about $70 million annually;
  
• SG&A spending near $185 million annually;
  
• Operating cash flow of about $450 million over three-year period;
  
• CAGRs:
  • Revs - 8 percent;
    
  • Adjusted GM - 11 percent;
    
  • Operating expense - 5 percent; and
    
  • Cash EPS - 15 percent.
• Cumulative cash flow of $400 million to $500 million

Par Pharma is now up about 3 percent Friday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Energy Vault’s 100 MW AI Infrastructure Project in Sardinia Receives Italian Government Designation as Project of Pre-Eminent National Strategic Interest
• Profound Medical names Richard Fabian as president
• XTEND deploys XOS-powered AtlasROVER to Asia-Pacific customer